Author:
Ash R J,Fite L D,Beight D W,Flynn G A
Abstract
Nontoxic analogs of sparsomycin were competitive inhibitors of puromycin in the peptidyl transferase assay with Escherichia coli polysomes. The sensitivity of HeLa cells in vitro to the analogs was used as a preliminary index of cellular toxicity. In vitro killing of HeLa cells by this class of compounds correlated well with in vivo 50% lethal doses. The data indicate that modification of the hydrophobic sulfoxide substituent on sparsomycin decreases the toxicity of the molecule for mammalian cells by several hundredfold. Such modifications have less of an effect on the inhibitory activity of the compounds for peptidyl transferase. The differential effects of an analog active against bacterial but not mammalian cells was due to a decreased uptake of the compound by HeLa cells.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference15 articles.
1. Screening of new and novel ,B lactam antibiotics;Aoki H.;Jpn. J. Antibiot.,1977
2. Ocular toxicity with sparsomycin (NSC-59729) in a phase I study: a preliminary report;Close H. P.;Cancer Chemother. Rep.,1964
3. Synthesis of sparsomycin analogs as potential antitumor agents;Dubois R. J.;J. Pharm. Sci.,1975
4. Necessity of the sulfoxide moiety for the biochemical and biological properties of an analog of sparsomycin;Flyan G. A.;Biochem. Biophys. Res. Commun.,1983
5. Use of Brij Iysis as a general method to prepare polyribosomes from Escherichia coli;Godson G. N.;Biochim. Biophys. Acta,1967
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献